

# Does a pre-operative subconjunctival injection of dexamethasone reduce the incidence of proliferative vitreoretinopathy in patients with ablatio retinae?

<b>Submission date</b> 20/12/2005	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
<b>Registration date</b> 20/12/2005	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
<b>Last Edited</b> 04/11/2010	<b>Condition category</b> Eye Diseases	<input type="checkbox"/> Individual participant data

**Plain English summary of protocol**  
Not provided at time of registration

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Dr J C van Meurs

**Contact details**  
Oogziekenhuis Rotterdam  
Schiedamsevest 180  
Rotterdam  
Netherlands  
3011 BH  
+31 (0)10 401 7777  
vanMeurs@oogziekenhuis.nl

## Additional identifiers

**Protocol serial number**  
OZR-2001-09; NTR194

## Study information

## Scientific Title

### Study objectives

A pre-operative subconjunctival injection of dexamethasone reduces the incidence of proliferative vitreoretinopathy in patients with ablatio retinae.

### Ethics approval required

Old ethics approval format

### Ethics approval(s)

Received from the local medical ethics committee

### Study design

Randomised double blind, placebo controlled, parallel group trial

### Primary study design

Interventional

### Study type(s)

Treatment

### Health condition(s) or problem(s) studied

Rhegmatogenous retinal detachment

### Interventions

Pre-operative and post-operative subconjunctival injection of dexamethasone (10 mg) or placebo.

### Intervention Type

Drug

### Phase

Not Specified

### Drug/device/biological/vaccine name(s)

Dexamethasone

### Primary outcome(s)

Incidence of proliferative vitreoretinopathy.

### Key secondary outcome(s)

No secondary outcome measures

### Completion date

22/01/2005

## Eligibility

### Key inclusion criteria

1. Primary rhegmatogenous retinal detachment
2. No previous ablation surgery

**Participant type(s)**

Patient

**Healthy volunteers allowed**

No

**Age group**

Adult

**Sex**

All

**Key exclusion criteria**

1. Diabetes mellitus
2. Systemic steroids
3. Steroid eye drops
4. Steroid glaucoma responder

**Date of first enrolment**

01/11/2002

**Date of final enrolment**

22/01/2005

**Locations****Countries of recruitment**

Netherlands

**Study participating centre**

Oogziekenhuis Rotterdam

Rotterdam

Netherlands

3011 BH

**Sponsor information****Organisation**

Rotterdam Eye Hospital (Oogziekenhuis Rotterdam) (The Netherlands)

**ROR**

<https://ror.org/02hjc7j46>

# Funder(s)

## Funder type

Research organisation

## Funder Name

Foundation of Scientific Research at the Eye Hospital (Stichting Wetenschappelijk Onderzoek het Oogziekenhuis) (The Netherlands)

# Results and Publications

## Individual participant data (IPD) sharing plan

## IPD sharing plan summary

Not provided at time of registration

## Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>	results	01/07/2010		Yes	No